Jamjoom Pharma Listed by everest Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

Jamjoom Pharma, a pharmaceutical manufacturer based in Jeddah, Saudi Arabia, was listed by the everest ransomware group on or around 1 May 2025. Public reporting indicates that internal files were exfiltrated in a ransomware attack; the number of people affected remains unknown and further technical details have not been disclosed.

Because the company develops and distributes prescription and over-the-counter medicines across domestic and international markets, any confirmed compromise of internal material carries potential consequences for patients, partners and the organisation itself. At present the listing itself is an unverified claim by the threat actor.

Inside the incident

According to available records, Jamjoom Pharma appeared on the everest group’s leak site with a report date of 1 May 2025. The sole concrete description provided is that internal files were allegedly exfiltrated during a ransomware attack. No public statement has confirmed the precise date of intrusion, the initial access vector, the volume of data taken, or whether encryption was also deployed on production systems. The number of individuals whose information may have been involved is listed as unknown. Until the company or independent investigators release additional findings, the scale and method of the incident remain undisclosed.

Inside everest

Everest is a ransomware operation that has been observed conducting double-extortion campaigns: after gaining access to a network the group typically steals data and then threatens to publish it unless a ransom is paid. Public reporting over recent years has associated everest with attacks on organisations across multiple sectors, often using phishing, compromised credentials or exploitation of remote-access services as entry points. Once inside, operators commonly move laterally, escalate privileges and stage data for exfiltration before deploying ransomware. The group maintains a dark-web leak site where it posts victim names and, in some cases, samples of stolen material to increase pressure. Its listing of Jamjoom Pharma should be treated as a claim by the actors rather than independently verified confirmation of every asserted detail.

Who is Jamjoom Pharma?

Jamjoom Pharma is a pharmaceutical company headquartered in Jeddah and formed in 2000 as part of the broader Jamjoom Group. It develops, manufactures and distributes a range of prescription medicines and over-the-counter products, with therapeutic focus areas that include dermatology, antibiotics, cardiovascular care, gastroenterology and neuropsychiatry. The firm serves both the Saudi domestic market and international customers. Organisations of this type routinely hold manufacturing records, quality-control data, regulatory filings, supplier contracts, employee information and, in some cases, limited patient or healthcare-provider data linked to product distribution and pharmacovigilance. A breach at such an entity therefore raises questions about the confidentiality of commercial and potentially regulated material.

What was likely exposed

The only data category named in the public record is “internal files” said to have been exfiltrated. Exact file names, volumes or categories have not been disclosed. Pharmaceutical companies of this profile commonly store research and development documents, batch-manufacturing records, quality-assurance reports, commercial contracts, employee personnel files and correspondence with regulators or distributors. Whether any of those specific classes of information were among the files taken in this incident is unconfirmed. Readers should treat any more granular claims circulating online as unverified until corroborated by the company or forensic investigators.

Why it matters

If internal files containing commercial or personal data were indeed removed, affected individuals could face risks of identity fraud, targeted phishing or unsolicited contact. For the organisation, exposure of proprietary manufacturing or regulatory material could create competitive harm, complicate compliance obligations and erode trust among healthcare partners and patients. Even when the precise contents remain unknown, the mere assertion of a ransomware-linked exfiltration is enough to warrant careful monitoring by anyone who has had a professional or commercial relationship with the company. The absence of confirmed victim counts does not eliminate the possibility that employees, contractors or business partners may be affected.

What to do if you're exposed

Anyone who believes their information may have been involved should begin by monitoring financial and email accounts for unusual activity and enabling multi-factor authentication wherever available. Consider placing fraud alerts with credit bureaus if personal identifiers were potentially held by the company. Employees or partners should follow any official guidance issued by Jamjoom Pharma’s security or human-resources teams. As an additional free step, individuals can run an exposure scan of their email address against known breach datasets to check whether their details have already appeared in public leak collections. Remain cautious of unsolicited messages that reference the incident and request personal information or payments.

AICompiled with AI assistance from public sources and published under our editorial standards.